Activin A and cardiovascular disease in type 2 diabetes mellitus

Diab Vasc Dis Res. 2012 Jul;9(3):234-7. doi: 10.1177/1479164111431171. Epub 2012 Jan 10.

Abstract

Background: Silent coronary artery disease is a frequent complication of type 2 diabetes (T2DM). Based on its multiple roles in inflammation, atherogenesis and glucose homeostasis, we hypothesised that activin A could be related to coronary atherosclerosis in T2DM.

Methods: Activin A and follistatin were measured in 102 patients with T2DM and 20 age- and sex-matched healthy controls. Coronary angiography was performed in a sub-population of patients and associations with activin A were examined using multiple linear regression.

Results: Serum activin A and the activin A/follistatin ratio were increased in patients with T2DM and coronary artery disease (CAD) compared with healthy volunteers and the elevated activin A was associated with the severity of coronary atherosclerotic burden as determined by the proportion of ≥2 vessel disease (p = 0.035) after multivariable-adjusted trend analysis. No significant association between presence of CAD or extent score and activin A was observed.

Conclusion: In patients with T2DM, increased activin A may reflect chronic underlying pathophysiological processes involved in development of cardiovascular disease.

MeSH terms

  • Activins / metabolism*
  • Adult
  • Aged
  • Case-Control Studies
  • Coronary Angiography
  • Coronary Artery Disease / etiology
  • Coronary Artery Disease / metabolism*
  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / metabolism*
  • Female
  • Follistatin / metabolism*
  • Humans
  • Inflammation / metabolism*
  • Linear Models
  • Male
  • Middle Aged

Substances

  • Follistatin
  • activin A
  • Activins